BALRAJ SINGH to Humans
This is a "connection" page, showing publications BALRAJ SINGH has written about Humans.
Connection Strength
0.110
-
Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge. PLoS One. 2016; 11(7):e0159072.
Score: 0.011
-
Highly adaptable triple-negative breast cancer cells as a functional model for testing anticancer agents. PLoS One. 2014; 9(10):e109487.
Score: 0.010
-
Selection of metastatic breast cancer cells based on adaptability of their metabolic state. PLoS One. 2012; 7(5):e36510.
Score: 0.008
-
Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines. J Surg Res. 2010 Oct; 163(2):235-43.
Score: 0.007
-
Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res. 2011 Jun 01; 168(1):e39-49.
Score: 0.007
-
Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin Exp Metastasis. 2010 Apr; 27(4):233-40.
Score: 0.007
-
Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. J Surg Res. 2008 Jun 15; 147(2):240-6.
Score: 0.006
-
Cyclooxygenase-2 expression induces genomic instability in MCF10A breast epithelial cells. J Surg Res. 2007 Jun 15; 140(2):220-6.
Score: 0.006
-
COX-2 involvement in breast cancer metastasis to bone. Oncogene. 2007 May 31; 26(26):3789-96.
Score: 0.006
-
Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. J Surg Res. 2006 Jul; 134(1):44-51.
Score: 0.006
-
COX-2 induces IL-11 production in human breast cancer cells. J Surg Res. 2006 Apr; 131(2):267-75.
Score: 0.005
-
COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol. 2005 May; 26(5):1393-9.
Score: 0.005
-
Role of cyclooxygenase-2 in breast cancer. J Surg Res. 2002 Nov; 108(1):173-9.
Score: 0.004
-
Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers. Int J Mol Sci. 2022 Jul 16; 23(14).
Score: 0.004
-
Mos and the cell cycle. Prog Cell Cycle Res. 1997; 3:251-9.
Score: 0.003
-
Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer. 2012 Jan 15; 118(2):342-8.
Score: 0.002
-
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. 2010 Jul 15; 116(14):3330-7.
Score: 0.002
-
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res. 2009 Nov 01; 15(21):6639-48.
Score: 0.002
-
A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug; 155(2):231-6.
Score: 0.002
-
Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat. 2009 Sep; 117(1):61-8.
Score: 0.002
-
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat. 2009 Feb; 113(3):501-7.
Score: 0.002
-
Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application? Expert Rev Anticancer Ther. 2007 Oct; 7(10):1463-72.
Score: 0.002
-
Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells. Cancer Res. 1998 Aug 15; 58(16):3633-40.
Score: 0.001
-
Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene. Oncogene. 1995 Dec 21; 11(12):2639-48.
Score: 0.001